Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.
OBJECTIVE
To compare the efficacy of cabergoline (Cb2) and intravenous human albumin (HA) in the prevention of ovarian hyperstimulation syndrome.


METHODS
In this randomized controlled trial study, 138 women who were at high risk for developing OHSS were randomly allocated into two groups. In Group one, 20 gr of HA 20% was infused over 1 h. Group two received 0.5 mg per day of Cb2 orally for 7 days, starting on oocyte pickup day. All patients were visited seven and 14 days after oocyte retrieval to determine early clinical or ultrasound evidence of OHSS.


RESULTS
Moderate OHSS was observed in 33 versus 14 cases in the HA and Cb2 groups, respectively, which was significantly different. The number of severe OHSS cases in the HA group was significantly higher than in the Cb2 group (P < 0.001).


CONCLUSIONS
Prophylactic oral low dose cabergoline was more effective and less costly than intravenous human albumin in the prevention of OHSS in high-risk patients.
Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Number 12, East Hafez Avenue, Bani Hashem Street, Resalat Highway, Tehran, Iran. tehraninejad@royaninstitute.org
Ensieh Shahrokh
ES
Tehraninejad
Maryam
M
Hafezi
Arezoo
A
Arabipoor
Elham
E
Aziminekoo
Mohammad
M
Chehrazi
Akram
A
Bahmanabadi
D000328:Adult; D000077465:Cabergoline; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D015994:Incidence; D007246:Infertility / Q000628:therapy*; D007262:Infusions, Intravenous; D007492:Iran / Q000453:epidemiology; D016471:Ovarian Hyperstimulation Syndrome / Q000209:etiology / Q000517:prevention & control*; D010062:Ovulation Induction / Q000009:adverse effects*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D012307:Risk Factors; D012709:Serum Albumin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000075462:Serum Albumin, Human; D012720:Severity of Illness Index; D020554:Sperm Injections, Intracytoplasmic; D055815:Young Adult
C422455:ALB protein, human; D015259:Dopamine Agents; D004873:Ergolines; D012709:Serum Albumin; D000077465:Cabergoline; D000075462:Serum Albumin, Human